Distinct patterns of cellular immune response elicited by influenza non-adjuvanted and AS03-adjuvanted monovalent H1N1(pdm09) vaccine

被引:9
|
作者
Giarola-Silva, Sarah [1 ]
Coelho-dos-Reis, Jordana G. A. [1 ]
Mourao, Marina Moraes [2 ]
Campi-Azevedo, Ana Carolina [1 ]
Nakagaki Silva, Erick E. [2 ]
Luiza-Silva, Maria [3 ]
Martins, Marina Angela [1 ]
de Oliveira Silveira-Cassette, Amanda Cardoso [1 ]
Batista, Mauricio Azevedo [1 ]
Peruhype-Magalhaes, Vanessa [1 ]
do Valle Antonelli, Lis Ribeiro [4 ]
Leite Ribeiro, Jose Geraldo [5 ]
Eloi-Santos, Silvana Maria [1 ,3 ]
Machado, Alexandre Vieira [6 ]
Teixeira-Carvalho, Andrea [1 ]
Martins-Filho, Olindo Assis [1 ]
Silva Araujo, Marcio Sobreira [1 ]
机构
[1] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Grp Integrado Pesquisas Biomarcadores, Belo Horizonte, MG, Brazil
[2] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Grp Helmintol & Malacol Med, Belo Horizonte, MG, Brazil
[3] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, MG, Brazil
[4] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Biol & Imunol Parasitaria, Belo Horizonte, MG, Brazil
[5] Secretaria Estadual Saude Minas Gerais, Belo Horizonte, MG, Brazil
[6] Fundacao Oswaldo Cruz FIOCRUZ Minas, Ctr Pesquisas Rene Rachou, Imunol Doencas Virais, Belo Horizonte, MG, Brazil
关键词
H1N1; vaccine; AS03; adjuvant; Immune response; Biomarker signature; PANDEMIC H1N1 INFLUENZA; ADVERSE EVENTS; AS03; ADJUVANT; B-LYMPHOCYTES; CHILDREN; CYTOKINE; AGE; IMMUNOGENICITY; INTERLEUKIN-10; SIGNATURES;
D O I
10.1016/j.antiviral.2017.05.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The study aimed at identifying biomarkers of immune response elicited by non-adjuvanted-(NAV) and adjuvanted-(AV) H1N1(pdm09) vaccines. The results showed that despite both vaccines elicited similar levels of anti-H1N1 antibodies at day30 after vaccination, higher reactivity was observed in AV at day180. While AV induced early changes in cell-surface molecules on monocytes, CD4(+), CDS+ T-cells and B-cells, NAV triggered minor changes, starting later on at day3. Furthermore, AV induced a late and persistent increase in TLR gene expression after day3, except for tIr4, while NAV displayed earlier but transient tlr3/4/7/9 up-regulation. Contrasting with NAV, prominent chemokine gene expression (cxcl8,cxcl9,ccl5) and a broad spectrum up-regulation of plasmatic biomarkers (CXCL8,1-6,1L-1 beta,1L-12,1-10) was evident in AV, which showed a major involvement of TNF and IL-10. Similarly, AV induced a robust IL-10-modulated proinflammatory storm, with early and persistent involvement of TNF-alpha/IL-12/IFN-gamma axis derived from NK-cells, CD4(+) and CD8(+) T-cells along with promiscuous production of IL-4/IL-5/1L-13. Conversely, NAV promotes a concise and restricted intracytoplasmic chemokine/cytokine response, essentially mediated by TNF-alpha and IL-4, with late IL-10 production by CD8(+) T-cells. Systems biology approach underscored that AV guided the formation of an imbricate network characterized by a progressive increase in the number of neighborhood connections amongst innate and adaptive immunity. In AV, the early cross-talk between innate and adaptive immunity, followed by the triad NK/CD4(+)/CD8(+) T-cells at day3, sponsored a later/robust biomarker network. These findings indicate the relevance of adjuvanted vaccination to orchestrate broad, balanced and multifactorial cellular immune events that lead ultimately to a stronger H1N1 humoral immunity. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:70 / 82
页数:13
相关论文
共 50 条
  • [31] Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine Two Open-label, Randomized Trials
    Vesikari, Timo
    Richardus, Jan Hendrik
    Berglund, Johan
    Korhonen, Tiina
    Flodmark, Carl-Erik
    Lindstrand, Ann
    Silfverdal, Sven Arne
    Bambure, Vinod
    Caplanusi, Adrian
    Dieussaert, Ilse
    Roy-Ghanta, Sumita
    Vaughn, David W.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (07) : 774 - 782
  • [32] A Prospective Study of the Factors Shaping Antibody Responses to the AS03-Adjuvanted Influenza A/H1N1 Vaccine in Cancer Outpatients
    Hottinger, Andreas F.
    George, Anne-Claude C.
    Bel, Michael
    Favet, Laurence
    Combescure, Christophe
    Meier, Sara
    Grillet, Stephane
    Posfay-Barbe, Klara
    Kaiser, Laurent
    Siegrist, Claire-Anne
    Dietrich, Pierre-Yves
    ONCOLOGIST, 2012, 17 (03): : 436 - 445
  • [33] Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months
    Carmona, Alfonso
    Omenaca, Felix
    Tejedor, Juan C.
    Merino, Jose M.
    Vaman, Tejaswini
    Dieussaert, Ilse
    Gillard, Paul
    Aristegui, Javier
    VACCINE, 2010, 28 (36) : 5837 - 5844
  • [34] AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice
    Caillet, Catherine
    Piras, Fabienne
    Bernard, Marie-Clotilde
    de Montfort, Aymeric
    Boudet, Florence
    Vogel, Frederick R.
    Hoffenbach, Agnes
    Moste, Catherine
    Kusters, Inca
    VACCINE, 2010, 28 (18) : 3076 - 3079
  • [35] Low response to a monovalent inactivated unadjuvanted influenza A (H1N1) pdm09 vaccine in pediatricians of a general hospital in Japan
    Hata, Atsuko
    Mano, Chihiro
    Nakamura, Yoshie
    Nishida, Hitoshi
    Kumakura, Akira
    Mizumoto, Hiroshi
    Yoshioka, Takakazu
    Yoshida, Yoko
    Shiota, Mitsutaka
    Hata, Daisuke
    Takahashi, Kazuo
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (05) : 587 - 591
  • [36] Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza. A vaccine in patients after haematopoietic stem cell transplantation
    Gueller, S.
    Mousset, S.
    Martin, H.
    Serve, H.
    Bug, G.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S218 - S218
  • [37] Relative Efficacy of AS03-Adjuvanted Pandemic Influenza A(H1N1) Vaccine in Children: Results of a Controlled, Randomized Efficacy Trial
    Nolan, Terry
    Roy-Ghanta, Sumita
    Montellano, May
    Weckx, Lily
    Ulloa-Gutierrez, Rolando
    Lazcano-Ponce, Eduardo
    Kerdpanich, Angkool
    Palazzi Safadi, Marco Aurelio
    Cruz-Valdez, Aurelio
    Litao, Sandra
    Lim, Fong Seng
    Mascarenas de Los Santos, Abiel
    Rodriguez Weber, Miguel Angel
    Tinoco, Juan-Carlos
    Hernandez-de Mezerville, Marcela
    Faingezicht, Idis
    Kosuwon, Pensri
    Lopez, Pio
    Borja-Tabora, Charissa
    Li, Ping
    Durviaux, Serge
    Fries, Louis
    Dubin, Gary
    Breuer, Thomas
    Innis, Bruce L.
    Vaughn, David W.
    JOURNAL OF INFECTIOUS DISEASES, 2014, 210 (04): : 545 - 557
  • [38] Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort study
    Nazareth, Irwin
    Tavares, Fernanda
    Rosillon, Dominique
    Haguinet, Francois
    Bauchau, Vincent
    BMJ OPEN, 2013, 3 (02):
  • [39] New patterns of A(H1N1)pdm09 influenza in the Southern Hemisphere
    Vandroux, David
    Brottet, Elise
    Ursulet, Lionel
    Angue, Marion
    Jabot, Julien
    Filleuil, Laurent
    Gauzere, Bernard-Alex
    INTENSIVE CARE MEDICINE, 2014, 40 (01) : 131 - +
  • [40] New patterns of A(H1N1)pdm09 influenza in the Southern Hemisphere
    David Vandroux
    Elise Brottet
    Lionel Ursulet
    Marion Angue
    Julien Jabot
    Laurent Filleuil
    Bernard-Alex Gauzere
    Intensive Care Medicine, 2014, 40 : 131 - 132